BACKGROUND AND PURPOSE: Piceatannol is more potent than resveratrol in free radical scavenging in association with antiarrhythmic and cardioprotective activities in ischaemic-reperfused rat hearts. The present study aimed to investigate the antiarrhythmic efficacy and the underlying ionic mechanisms of piceatannol in rat hearts. EXPERIMENTAL APPROACH: Action potentials and membrane currents were recorded by the whole-cell patch clamp techniques. Fluo-3 fluorimetry was used to measure cellular Ca2+ transients. Antiarrhythmic activity was examined from isolated Langendorff-perfused rat hearts. KEY RESULTS: In rat ventricular cells, piceatannol (3-30 micromol.L(-1)) prolonged the action potential durations (APDs) and decreased the maximal rate of upstroke (V(max)) without altering Ca2+ transients. Piceatannol decreased peak I(Na) and slowed I(Na) inactivation, rather than induced a persistent non-inactivating current, which could be reverted by lidocaine. Resveratrol (100 micromol.L(-1)) decreased peak I(Na) without slowing I(Na) inactivation. The inhibition of peak I(Na) or V(max) was associated with a negative shift of the voltage-dependent steady-state I(Na) inactivation curve without altering the activation threshold. At the concentrations more than 30 micromol.L(-1), piceatannol could inhibit I(Ca,L), I(to), I(Kr), Ca2+ transients and Na+-Ca2+ exchange except I(K1). Piceatannol (1-10 micromol.L(-1)) exerted antiarrhythmic activity in isolated rat hearts subjected to ischaemia-reperfusion injury. CONCLUSIONS AND IMPLICATIONS: The additional hydroxyl group on resveratrol makes piceatannol possessing more potent in I(Na) inhibition and uniquely slowing I(Na) inactivation, which may contribute to its antiarrhythmic actions at low concentrations less than 10 micromol.L(-1).
BACKGROUND AND PURPOSE:Piceatannol is more potent than resveratrol in free radical scavenging in association with antiarrhythmic and cardioprotective activities in ischaemic-reperfused rat hearts. The present study aimed to investigate the antiarrhythmic efficacy and the underlying ionic mechanisms of piceatannol in rat hearts. EXPERIMENTAL APPROACH: Action potentials and membrane currents were recorded by the whole-cell patch clamp techniques. Fluo-3 fluorimetry was used to measure cellular Ca2+ transients. Antiarrhythmic activity was examined from isolated Langendorff-perfused rat hearts. KEY RESULTS: In rat ventricular cells, piceatannol (3-30 micromol.L(-1)) prolonged the action potential durations (APDs) and decreased the maximal rate of upstroke (V(max)) without altering Ca2+ transients. Piceatannol decreased peak I(Na) and slowed I(Na) inactivation, rather than induced a persistent non-inactivating current, which could be reverted by lidocaine. Resveratrol (100 micromol.L(-1)) decreased peak I(Na) without slowing I(Na) inactivation. The inhibition of peak I(Na) or V(max) was associated with a negative shift of the voltage-dependent steady-state I(Na) inactivation curve without altering the activation threshold. At the concentrations more than 30 micromol.L(-1), piceatannol could inhibit I(Ca,L), I(to), I(Kr), Ca2+ transients and Na+-Ca2+ exchange except I(K1). Piceatannol (1-10 micromol.L(-1)) exerted antiarrhythmic activity in isolated rat hearts subjected to ischaemia-reperfusion injury. CONCLUSIONS AND IMPLICATIONS: The additional hydroxyl group on resveratrol makes piceatannol possessing more potent in I(Na) inhibition and uniquely slowing I(Na) inactivation, which may contribute to its antiarrhythmic actions at low concentrations less than 10 micromol.L(-1).
Authors: Bharat B Aggarwal; Gautam Sethi; Kwang Seok Ahn; Santosh K Sandur; Manoj K Pandey; Ajaikumar B Kunnumakkara; Bokyung Sung; Haruyo Ichikawa Journal: Ann N Y Acad Sci Date: 2006-12 Impact factor: 5.691
Authors: G A Potter; L H Patterson; E Wanogho; P J Perry; P C Butler; T Ijaz; K C Ruparelia; J H Lamb; P B Farmer; L A Stanley; M D Burke Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640
Authors: Carlos Henrique Lima Imperador; Cauê Benito Scarim; Priscila Longhin Bosquesi; Juliana Romano Lopes; Augusto Cardinalli Neto; Jeanine Giarolla; Elizabeth Igne Ferreira; Jean Leandro Dos Santos; Chung Man Chin Journal: Pharmaceuticals (Basel) Date: 2022-05-15
Authors: E Hijona; L Aguirre; P Pérez-Matute; M J Villanueva-Millán; A Mosqueda-Solis; M Hasnaoui; F Nepveu; J M Senard; L Bujanda; L Aldámiz-Echevarría; M Llarena; F Andrade; P Perio; F Leboulanger; L Hijona; J M Arbones-Mainar; M P Portillo; C Carpéné Journal: J Physiol Biochem Date: 2016-01-20 Impact factor: 4.158